ARTICLE | Finance
Karuna’s CNS double play
How Karuna plans to deploy $42M A round to revive xanomeline’s development
August 3, 2018 8:43 PM UTC
With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies.
Along with founding investor PureTech Health PLC (LSE:PRTC), the round included Arch Venture Partners, the Wellcome Trust and Karuna Chairman Steven Paul, as well as undisclosed other backers...